Zoetis Investigated for EU Antitrust Breach Over Dog Pain Drug

The European Commission is investigating whether US animal health company Zoetis Inc. breached antitrust laws by preventing the market launch of a competing medicine to treat chronic pain in dogs.

Zoetis, which was spun out of Pfizer Inc. over a decade ago, makes Librela, the only monoclonal antibody drug currently approved in Europe to treat osteoarthritis pain in dogs.

The commission said Tuesday that it’s concerned that alongside developing Librela, Zoetis also bought a similar late-stage pipeline product only to then cancel the launch of that drug and refuse to transfer it to a third party that had exclusive commercialization ...